The Hyderabad headquartered vaccine maker has recently received approvals from the drug regulator to carry out paediatric trials of the vaccine.
“It will be a trial on children aged 2-18 years,” said Raches Ella, Bharat Bio’s head-business development and international advocacy, addressing a Ficci Ladies Organisation (FLO) meeting in Hyderabad on Saturday.
“Kids vaccine trials of Bharat Biotech may get the license in the third quarter of this year.”
“A few of our products in the past got their approval. We expect approval for Covaxin by the end of Q3 or Q4,” said Raches Ella.